Journal of International Oncology ›› 2025, Vol. 52 ›› Issue (3): 152-157.doi: 10.3760/cma.j.cn371439-20231016-00023
• Original Article • Previous Articles Next Articles
Wang Yi1, Wang Qiangli1, Zhang Jia1, Yang Yijin1, Wang Sheng2()
Received:
2023-10-16
Revised:
2023-12-27
Online:
2025-03-08
Published:
2025-04-02
Contact:
Wang Sheng,Email:Wang Yi, Wang Qiangli, Zhang Jia, Yang Yijin, Wang Sheng. Relationship between the expression of SUCNR1 and YBX1 in tissues of patients with colorectal cancer liver metastases and their clinicopathological characteristics and prognosis[J]. Journal of International Oncology, 2025, 52(3): 152-157.
"
临床病理特征 | SUCNR1 | χ2值 | P值 | YBX1 | χ2值 | P值 | ||
---|---|---|---|---|---|---|---|---|
高表达(n=78) | 低表达(n=27) | 高表达(n=89) | 低表达(n=16) | |||||
性别 | ||||||||
男 | 52(66.67) | 20(74.07) | 0.51 | 0.475 | 60(67.42) | 12(75.00) | 0.36 | 0.547 |
女 | 26(33.33) | 7(25.93) | 29(32.58) | 4(25.00) | ||||
年龄(岁) | ||||||||
≥60 | 38(48.72) | 11(40.74) | 0.51 | 0.474 | 41(46.07) | 8(50.00) | 0.08 | 0.772 |
<60 | 40(51.28) | 16(59.26) | 48(53.93) | 8(50.00) | ||||
原发部位 | ||||||||
结肠 | 53(67.95) | 22(81.48) | 1.80 | 0.180 | 62(69.66) | 13(81.25) | 0.42 | 0.520 |
直肠 | 25(32.05) | 5(18.52) | 27(30.34) | 3(18.75) | ||||
原发肿瘤类型 | ||||||||
腺癌 | 74(94.87) | 25(92.59) | <0.01 | >0.999 | 84(94.38) | 15(93.75) | 0.24 | 0.628 |
非腺癌 | 4(5.13) | 2(7.41) | 5(5.62) | 1(6.25) | ||||
组织学分级 | ||||||||
Ⅰ~Ⅱ级 | 51(65.38) | 25(92.59) | 7.43 | 0.006 | 61(68.54) | 15(93.75) | 3.14 | 0.076 |
Ⅲ~Ⅳ级 | 27(34.62) | 2(7.41) | 28(31.46) | 1(6.25) | ||||
T分期 | ||||||||
T1-2 | 14(19.95) | 9(33.33) | 2.78 | 0.096 | 17(19.10) | 6(37.50) | 1.72 | 0.190 |
T3-4 | 64(82.05) | 18(66.67) | 72(80.90) | 10(62.50) | ||||
N分期 | ||||||||
N0 | 19(24.36) | 10(37.04) | 2.78 | 0.249 | 23(25.84) | 6(37.50) | 1.14 | 0.564 |
N1 | 29(37.18) | 11(40.74) | 34(38.20) | 6(37.50) | ||||
N2 | 30(38.46) | 6(22.22) | 32(35.96) | 4(25.00) | ||||
肝转移部位 | ||||||||
左或右半肝 | 51(65.38) | 23(85.19) | 3.78 | 0.052 | 61(68.54) | 13(81.25) | 0.53 | 0.466 |
双侧肝 | 27(34.62) | 4(14.81) | 28(31.46) | 3(18.75) | ||||
肝转移距结直肠癌确诊时间(年) | ||||||||
≤3 | 57(73.08) | 11(40.74) | 9.19 | 0.002 | 64(71.91) | 4(25.00) | 13.08 | <0.001 |
>3 | 21(26.92) | 16(59.26) | 25(28.09) | 12(75.00) | ||||
转移病灶数目(个) | ||||||||
1~3 | 63(80.77) | 25(92.59) | 1.29 | 0.257 | 72(80.90) | 16(100) | 2.38 | 0.123 |
>3 | 15(19.23) | 2(7.41) | 17(19.10) | 0(0) | ||||
转移灶最大直径(cm) | ||||||||
>3 | 56(71.79) | 16(59.26) | 1.46 | 0.227 | 63(70.79) | 9(56.25) | 1.33 | 0.249 |
≤3 | 22(28.21) | 11(40.74) | 26(29.21) | 7(43.75) | ||||
同时性肝转移 | ||||||||
是 | 29(37.18) | 5(18.52) | 3.19 | 0.074 | 32(35.96) | 2(12.50) | 3.41 | 0.065 |
否 | 49(62.82) | 22(81.48) | 57(64.04) | 14(87.50) | ||||
手术切缘(cm) | ||||||||
≤1 | 23(29.49) | 9(33.33) | 0.14 | 0.708 | 27(30.34) | 5(31.25) | 0.24 | 0.628 |
>1 | 55(70.51) | 18(66.67) | 62(69.66) | 11(68.75) | ||||
肝外转移 | ||||||||
有 | 16(20.51) | 2(7.41) | 1.59 | 0.207 | 18(20.22) | 0(0) | 2.61 | 0.106 |
无 | 62(79.49) | 25(92.59) | 71(79.78) | 16(100) |
[1] | Li J, Ma X, Chakravarti D, et al. Genetic and biological hallmarks of colorectal cancer[J]. Genes Dev, 2021, 35(11-12): 787-820. DOI: 10.1101/gad.348226.120. |
[2] |
Aykut B, Lidsky ME. Colorectal cancer liver metastases: multimodal therapy[J]. Surg Oncol Clin N Am, 2023, 32(1): 119-141. DOI: 10.1016/j.soc.2022.07.009.
pmid: 36410912 |
[3] | Wu JY, Huang TW, Hsieh YT, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor[J]. Mol Cell, 2020, 77(2): 213-227.e5. DOI: 10.1016/j.molcel.2019.10.023. |
[4] |
Chen J, Li Z, Yue C, et al. Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis[J]. Apoptosis, 2023, 28(3-4): 549-565. DOI: 10.1007/s10495-022-01798-x.
pmid: 36652132 |
[5] | 裴正浩, 张虎, 王钧, 等. YBX1和FOXA1在胃癌中的表达及其临床病理学意义[J]. 肿瘤防治研究, 2022, 49(11): 1159-1164. DOI: 10.3971/j.issn.1000-8578.2022.22.0189. |
[6] | Zhao Y, Yang S, Nie H, et al. Promotion of colorectal cancer progression by immune-related lnc-SOX9-4 via suppression of YBX1 poly-ubiquitination and degradation[J]. Cell Signal, 2023, 111: 110854. DOI: 10.1016/j.cellsig.2023.110854. |
[7] |
Monteiro LS, Diniz-Freitas M, Warnakulasuriya S, et al. An immunohistochemical score to predict the outcome for oral squamous cell carcinoma[J]. J Oral Pathol Med, 2018, 47(4): 375-381. DOI: 10.1111/jop.12682.
pmid: 29344992 |
[8] |
Wang Y, Zhong X, He X, et al. Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches[J]. J Exp Clin Cancer Res, 2023, 42(1): 177-205. DOI: 10.1186/s13046-023-02729-7.
pmid: 37480104 |
[9] | Atallah R, Olschewski A, Heinemann A. Succinate at the crossroad of metabolism and angiogenesis: roles of SDH, HIF1α and SUCNR1[J]. Biomedicines, 2022, 10(12): 3089. DOI: 10.3390/biomedicines10123089. |
[10] | Chen J, Cao L, Ma J, et al. HDAC8 promotes liver metastasis of colorectal cancer via inhibition of IRF1 and upregulation of SUCNR1[J]. Oxid Med Cell Longev, 2022, 2022: 2815187. DOI: 10.1155/2022/2815187. |
[11] | 谷春杰. 琥珀酸脱氢酶B在子宫内膜癌中表达和作用机制研究[D]. 无锡: 江南大学, 2018. |
[12] | Chen S, Li K, Guo J, et al. circNEIL3 inhibits tumor metastasis through recruiting the E3 ubiquitin ligase Nedd4L to degrade YBX1[J]. Proc Natl Acad Sci U S A, 2023, 120(13): e2215132120. DOI: 10.1073/pnas.2215132120. |
[13] | 窦娟, 李恒宇, 陈静, 等. CK2α在甲状腺肿瘤中的表达及其在癌转移中的作用机制研究[J]. 肿瘤代谢与营养电子杂志, 2021, 8(3): 261-266. |
[14] | 苏靖. YBX1与G3BP1相互作用调控SPP1促进肾癌转移的机制研究[D]. 天津: 天津医科大学, 2019. |
[15] |
Cui G, Zhao H, Li L. Long noncoding RNA PRKCQ-AS1 promotes CRC cell proliferation and migration via modulating miR-1287-5p/YBX1 axis[J]. J Cell Biochem, 2020, 121(10): 4166-4175. DOI: 10.1002/jcb.29712.
pmid: 32619070 |
[1] | Yang Shengjun, Ren Jiang, Yang Dan, Long Yu, Shang Qunxian. Expression levels and clinical significance of miR-4262,NRG1 in non-small cell lung cancer tissues [J]. Journal of International Oncology, 2025, 52(3): 129-135. |
[2] | Han Tao, Jia Peipei, Lu Jing. Predictive value of iRhom1,iRhom2 and TNF-α levels for the prognosis of patients with cervical cancer [J]. Journal of International Oncology, 2025, 52(3): 158-162. |
[3] | Ye Yongying, Zou Yan, Chen Tianming, Wu Weili. Research progress of clock gene Period family in head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2025, 52(2): 113-118. |
[4] | Chen Danlei, Deng Junjun, Li Miao. Progress of clinical application of circulating tumor cells in lung cancer [J]. Journal of International Oncology, 2025, 52(2): 119-123. |
[5] | Wang Zhibao, Li Guangxian, Zhang Xinxin, Cui Wei, Zhang Wei. Predictive value of MRI combined with serum lncRNA KCNQ1OT1, miR-204-5p for axillary lymph node metastasis of breast cancer [J]. Journal of International Oncology, 2025, 52(2): 89-93. |
[6] | Ji Haitao, Wang Yanfeng, Liu Yongcheng, Hao Nan. Expression and clinical significance of DHCR7 in gastric cancer based on bioinformatics analysis [J]. Journal of International Oncology, 2025, 52(2): 94-100. |
[7] | Yu Yang, Tang Shimin, Yang Lu, Li Na. Research progress in treatment strategies and prognostic factors for stage pT2-3N0M0 thoracic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2025, 52(1): 43-47. |
[8] | Zhan Haifeng, Tan Zixuan, Wang Wenxue, Geng Jiawei. Research progress of circadian genes in the occurrence, development and chronotherapy of colorectal cancer [J]. Journal of International Oncology, 2025, 52(1): 60-64. |
[9] | Wei Wei, Cai Zhaoying, Qian Yayun. Effect of Marsdenia tenacissima combined with XELOX solution on disulfide apoptosis in human colorectal cancer HCT116 cells [J]. Journal of International Oncology, 2024, 51(9): 545-555. |
[10] | Yuan Shengfang, Ren Jie, Lin Weijia, Ji Zexuan, Zhang Changhong, Wang Bu. Prognostic value of EGFR co-mutation status in patients with advanced lung adenocarcinoma [J]. Journal of International Oncology, 2024, 51(9): 556-562. |
[11] | Zhan Haifeng, Wang Wenxue, Geng Jiawei. Research progress in precise molecular targeted therapy for advanced colorectal cancer [J]. Journal of International Oncology, 2024, 51(9): 601-605. |
[12] | Ni Guoying, Huang Qian, Liang Hongxiang, Yang Zhiyong, Ding Yingli. Analysis of changes in serum miR-499 and miR-362 levels and their relationship with prognosis in advanced NSCLC patients [J]. Journal of International Oncology, 2024, 51(8): 487-492. |
[13] | Meng Kexin, Lu Haijun. Oral microbiota:a biomarker for the diagnosis and prognosis of oral squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(8): 515-519. |
[14] | Li Zhiwei, Zhai Chunbao. Research progress on the anti-cancer effect of traditional Chinese medicine polyphenols on colorectal cancer [J]. Journal of International Oncology, 2024, 51(8): 526-531. |
[15] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 1
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 6
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||